The Challenge of Achieving Immunity Through Multiple-Dose Vaccines in Madagascar.


Journal

American journal of epidemiology
ISSN: 1476-6256
Titre abrégé: Am J Epidemiol
Pays: United States
ID NLM: 7910653

Informations de publication

Date de publication:
01 10 2021
Historique:
received: 28 06 2020
revised: 09 05 2021
accepted: 13 05 2021
pubmed: 24 5 2021
medline: 21 10 2021
entrez: 23 5 2021
Statut: ppublish

Résumé

Administration of many childhood vaccines requires that multiple doses be delivered within a narrow time window to provide adequate protection and reduce disease transmission. Accurately quantifying vaccination coverage is complicated by limited individual-level data and multiple vaccination mechanisms (routine and supplementary vaccination programs). We analyzed 12,541 vaccination cards from 6 districts across Madagascar for children born in 2015 and 2016. For 3 vaccines-pentavalent diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine (DTP-HB-Hib; 3 doses), 10-valent pneumococcal conjugate vaccine (PCV10; 3 doses), and rotavirus vaccine (2 doses)-we used dates of vaccination and birth to estimate coverage at 1 year of age and timeliness of delivery. Vaccination coverage at age 1 year for the first dose was consistently high, with decreases for subsequent doses (DTP-HB-Hib: 91%, 81%, and 72%; PCV10: 82%, 74%, and 64%; rotavirus: 73% and 63%). Coverage levels between urban districts and their rural counterparts did not differ consistently. For each dose of DTP-HB-Hib, the overall percentage of individuals receiving late doses was 29%, 7%, and 6%, respectively; estimates were similar for other vaccines. Supplementary vaccination weeks, held to help children who had missed routine care to catch up, did not appear to increase the likelihood of being vaccinated. Maintaining population-level immunity with multiple-dose vaccines requires a robust stand-alone routine immunization program.

Identifiants

pubmed: 34023892
pii: 6280147
doi: 10.1093/aje/kwab145
pmc: PMC9630123
doi:

Substances chimiques

10-valent pneumococcal conjugate vaccine 0
Diphtheria-Tetanus-Pertussis Vaccine 0
Haemophilus Vaccines 0
Pneumococcal Vaccines 0
Rotavirus Vaccines 0
Vaccines 0
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2085-2093

Subventions

Organisme : NLM NIH HHS
ID : DP2 LM013102
Pays : United States

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Bull World Health Organ. 2005 Jul;83(7):503-10
pubmed: 16175824
J Infect Dis. 2008 May 15;197(10):1427-35
pubmed: 18419577
BMC Public Health. 2011 May 27;11:404
pubmed: 21619642
Vaccine. 2019 Apr 24;37(18):2511-2519
pubmed: 30940486
J Infect Dis. 2011 Jul;204 Suppl 1:S343-52
pubmed: 21666183
PLoS One. 2012;7(6):e38370
pubmed: 22675551
BMJ. 2003 Apr 19;326(7394):852-3
pubmed: 12702617
Wkly Epidemiol Rec. 2015 Aug 28;90(35):433-58
pubmed: 26320265
Front Immunol. 2014 Sep 16;5:446
pubmed: 25278941
BMC Public Health. 2016 Feb 19;16:172
pubmed: 26895838
Am J Prev Med. 2000 Oct;19(3 Suppl):89-98
pubmed: 11024333
Epidemiol Infect. 2002 Apr;128(2):185-92
pubmed: 12002536
Sci Transl Med. 2019 Aug 14;11(505):
pubmed: 31413144
World Health Stat Q. 1988;41(2):59-63
pubmed: 3176515
Health Policy. 2007 Sep;83(1):27-36
pubmed: 17174435
Am J Epidemiol. 2018 Oct 1;187(10):2219-2226
pubmed: 29878051
Epidemiol Rev. 1993;15(2):265-302
pubmed: 8174658
Epidemiol Infect. 2015 May;143(7):1457-66
pubmed: 25119237
Vaccine. 2003 Jan 30;21(7-8):596-600
pubmed: 12531324
Wkly Epidemiol Rec. 2013 Feb 1;88(5):49-64
pubmed: 23424730
Lancet Infect Dis. 2017 Oct;17(10):1089-1097
pubmed: 28807627
Eur J Pediatr. 1997 Apr;156(4):282-7
pubmed: 9128812
Nat Rev Immunol. 2009 Mar;9(3):185-94
pubmed: 19240757
Vaccine. 2007 Jan 8;25(4):588-90
pubmed: 16971026
Proc Biol Sci. 2003 Jun 7;270(1520):1129-36
pubmed: 12816650
J Infect Dis. 2018 Jul 2;218(3):355-364
pubmed: 29562334
BMC Health Serv Res. 2015 Sep 02;15:358
pubmed: 26328630

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH